IRIS

Previous trials suggest that vasopressin may improve outcomes in patients with vasodilatory shock. The aim of this study was to evaluate whether vasopressin could be superior to norepinephrine to improve outcomes in cancer patients with septic shock.

Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial

Landoni, Giovanni
Ultimo
2019-01-01

Abstract

Previous trials suggest that vasopressin may improve outcomes in patients with vasodilatory shock. The aim of this study was to evaluate whether vasopressin could be superior to norepinephrine to improve outcomes in cancer patients with septic shock.
2019
Inglese
47
12
1743
1750
8
Pubblicato
2-s2.0-85075110528
WOS:000497830500036
Sì
UNISR.MED
OSR
none
14
info:eu-repo/semantics/article
262
Hajjar, Ludhmila Abrahão; Zambolim, Cristiane; Belletti, Alessandro; de Almeida, Juliano Pinheiro; Gordon, Anthony C; Oliveira, Gisele; Park, Clarice ...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/94525
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 42
social impact